1. Home
  2. AKTX vs SAIH Comparison

AKTX vs SAIH Comparison

Compare AKTX & SAIH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • SAIH
  • Stock Information
  • Founded
  • AKTX N/A
  • SAIH 2019
  • Country
  • AKTX United States
  • SAIH Singapore
  • Employees
  • AKTX 12
  • SAIH N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • SAIH
  • Sector
  • AKTX Health Care
  • SAIH
  • Exchange
  • AKTX Nasdaq
  • SAIH NYSE
  • Market Cap
  • AKTX 35.7M
  • SAIH 12.3M
  • IPO Year
  • AKTX N/A
  • SAIH N/A
  • Fundamental
  • Price
  • AKTX $1.14
  • SAIH $8.00
  • Analyst Decision
  • AKTX
  • SAIH
  • Analyst Count
  • AKTX 0
  • SAIH 0
  • Target Price
  • AKTX N/A
  • SAIH N/A
  • AVG Volume (30 Days)
  • AKTX 25.6K
  • SAIH 24.3K
  • Earning Date
  • AKTX 08-18-2025
  • SAIH 04-28-2025
  • Dividend Yield
  • AKTX N/A
  • SAIH N/A
  • EPS Growth
  • AKTX N/A
  • SAIH N/A
  • EPS
  • AKTX N/A
  • SAIH N/A
  • Revenue
  • AKTX N/A
  • SAIH $5,543,000.00
  • Revenue This Year
  • AKTX N/A
  • SAIH N/A
  • Revenue Next Year
  • AKTX N/A
  • SAIH N/A
  • P/E Ratio
  • AKTX N/A
  • SAIH N/A
  • Revenue Growth
  • AKTX N/A
  • SAIH N/A
  • 52 Week Low
  • AKTX $0.85
  • SAIH $3.00
  • 52 Week High
  • AKTX $4.40
  • SAIH $26.98
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 43.82
  • SAIH N/A
  • Support Level
  • AKTX $1.10
  • SAIH N/A
  • Resistance Level
  • AKTX $1.18
  • SAIH N/A
  • Average True Range (ATR)
  • AKTX 0.05
  • SAIH 0.00
  • MACD
  • AKTX 0.00
  • SAIH 0.00
  • Stochastic Oscillator
  • AKTX 39.52
  • SAIH 0.00

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About SAIH SAIHEAT LIMITED

Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.

Share on Social Networks: